ACETAMINOPHEN and CODEINE PHOSPHATE ORAL SOLUTION USP, 120 mg/12 mg per 5 mL, packaged in a) 4 oz...

FDA Drug Recall #D-0331-2015 - Class III, December 22, 2014

Recall Summary

Recall Number D-0331-2015
Classification Class III, Low risk
Date Initiated December 22, 2014
Status Terminated
Voluntary Voluntary: Firm initiated

Recalling Firm

Firm Qualitest Pharmaceuticals
Location Huntsville, AL
Product Type Drugs
Quantity a) 3936 bottles; b) 84420 bottles

Product Description

ACETAMINOPHEN and CODEINE PHOSPHATE ORAL SOLUTION USP, 120 mg/12 mg per 5 mL, packaged in a) 4 oz. (120 mL) bottles, NDC 0603-9013-54, UPC 3 0603-9013-54 8 and b) ONE PINT (473 mL) bottles, NDC 0603-9013-58, UPC 3 0603-9013-58 6, Rx only, Manufactured for: QUALITEST PHARMACEUTICALS, HUNTSVILLE, AL 35811

Reason for Recall

Failed Impurities/Degradation Specifications: High out of specification results for the known impurity p-Aminophenol.

Distribution Pattern

Nationwide

Lot / Code Information

Lot #: a) L140H13B, Exp. 03/15; L001D14A. Exp. 08/15; b) L140H13A, Exp. 03/15; L205K13A, Exp. 05/15; L019L13A, L020L13A, Exp. 06/15; L001D14B, 08/15; L091D14A, Exp. 10/15

Other Recalls from Qualitest Pharmaceuticals

Recall # Classification Product Date
D-1405-2015 Class III ALLOPURINOL TABLETS, USP, 300 mg, 500 count bot... Jul 20, 2015
D-1239-2015 Class III HydrOXYzine Hydrochloride Tablets, USP 25 mg, ... Jun 29, 2015
D1151-2015 Class III Disulfiram tablets, USP, 500 mg, 100-count bott... Jun 18, 2015
D00432-2015 Class III PROMETHAZINE VC WITH CODEINE SYRUP, EACH 5 ml c... Mar 25, 2015
D-0411-2015 Class II PROMETHAZINE DM SYRUP (Promethazine Hydrochlori... Feb 23, 2015

Frequently Asked Questions

Nitrosamines are probable human carcinogens, they can increase cancer risk with long-term exposure above certain thresholds, but they do not cause immediate harm from taking a single dose. The FDA calculates an acceptable daily intake (ADI) for each nitrosamine compound, and recalls are triggered when levels exceed this threshold. If you have been taking a recalled product, the FDA generally advises against abruptly stopping your medication (especially for critical conditions like blood pressure or diabetes) until you consult your doctor. The incremental cancer risk from short-term exposure is very small.

Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications, even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.

Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.

What Should You Do?

Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications, use a drug take-back program.